Navigation Links
Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Date:11/17/2010

ther increasing this successful rate to 80% in its Phase III clinical program.

Dr. Christian Homsy, CEO of Cardio3 BioSciences said: "The highly promising data we report today build on the favourable safety profile we have observed through this Phase II trial and documents in patients our belief that we have with C-Cure a product candidate with the potential to make a real difference in the treatment of heart failure. It is important to note that the improvements in heart function suggested by the trial, were identified in the context of a Phase II trial aimed at assessing the safety and feasibility of C-Cure therapy. It is all the more encouraging to have seen significant differences in some key efficacy indicators despite the fact that the study was not powered, in terms of the number of patients, to demonstrate efficacy."

"As noted in the company's press release of 29 June 2010, with the Phase II stage completed and to allow for potential modifications to the trial protocol, Cardio3 BioSciences has not proceeded to Phase III recruitment into the trial but has continued to gather all data for the six month analysis."

"Through the Phase II trial, we gained significant experience in working with a highly innovative stem cell therapy in a clinical setting, and we are using this acquired knowledge in the design of our planned Phase III programme. Cardio3 BioSciences is committed in taking the steps needed to bring to patients a new treatment for a condition where current therapies do not address the underlying cause of the disease."

Dr. Jozef Bartunek, Associate Director of the Cardiovascular Center in Aalst, Belgium and Co-Principal Investigator of the C-Cure Clinical Trial added: "The data reported today are very positive for this 'first in man' trial using stem cells 'directed' to become heart cells. Early efficacy signals are impressive as they come on top of the optimal therapy currently available for patients with heart failure. T
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
2. Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
3. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
4. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
6. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
7. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
8. Ambit Biosciences Strengthens Board of Directors and Executive Team
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 The ... the five years to 2014. Industry operators were able ... during the period, as well as establish distribution contracts ... due in large part to its novelty; energy drinks ... in that time, industry operators have been able to ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... for the 2014 NEXT Awards in the Technology ... has been selected as the sole female finalist ... Chamber of Commerce and the Nashville Entrepreneur Center ... accomplishments of companies and individual entrepreneurs in five ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Buoyed by technological advancements, surgical techniques, and ... become the preferred treatment for several chronic diseases ... liver. Advancements in organ and tissue transplantation have ... patients. Organ transplant today represents a ...
(Date:9/19/2014)... researchers at the University of Utah School of Medicine ... of mitochondria in debilitating and fatal motor neuron diseases ... such illnesses. , Researchers led ... when healthy, functioning mitochondria was prevented from moving along ... neurons mice developed symptoms of neurodegenerative diseases. In ...
(Date:9/19/2014)... grow well in infertile land, and bear many beans ... is because most legumes have a symbiotic relationship with ... air and then supply the host plant with ammonia ... organs called nodules in their roots. However, if too ... the growth of the plants, because the energy cost ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Long-distance communication from leaves to roots 2
... June 29 Medicsight PLC, a subsidiary of MGT Capital ... industry leader in the development of Computer-Aided Detection (CAD) and ... of disease, is pleased to announce the launch of its ... benefits of Medicsight,s ColonCAD software truly accessible to all radiologists ...
... , LONDON, June 29 The Healthcare Group at ... Quarterly Analyst Briefing Presentation on the European Hospital Information Systems ... at 2 p.m. GMT. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... some kind of information system in place, only a few ...
... Clarient, Inc. (Nasdaq: ... services resource for pathologists, oncologists and the pharmaceutical industry, today announced ... Index when Russell Investments reconstitutes its comprehensive set of U.S. and ... of additions posted June 12 on www.russell.com . ...
... ... your pet healthy and happy and is more likely to avoid serious and costly health problems ... ... health care can prevent expensive vet bills in the future, pet owners are reminded, as everyone continues ...
... Florida,s First Certified Urgent ... County Florida has become the first in the State to receive formal recognition as a Certified ... ... Care Medical Centers of Palm Beach County Florida has become the first in the State to ...
... ... to access critical health data stored in electronic health records (EHRs). The company has just ... , ... 29, 2009 -- Orion Health , a market leader in providing clinical workflow and ...
Cached Medicine News:Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 2Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 3Health News:Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value 2Health News:Clarient Set to Join Russell 3000 Index 2Health News:Clarient Set to Join Russell 3000 Index 3Health News:Clarient Set to Join Russell 3000 Index 4Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 2Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 3Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 2Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 3
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
Medicine Products: